L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
32-year-old man: hair loss since his lates twenties
- 5min (reading time)
- Sep. 2023
- Supported by
Clinical Case provided by Dr María Eugenia Cappetta
Dermatologist, Head of Hair & Scalp Disorders subsection at Buenos Aires Skin Dermatologic Center, Argentina
- 32-year-old man
- Main complaint: hair loss since his lates twenties
- Family history of baldness (father and grandfather)
- Clinical Scalp exam: hair loss mainly in vertex. Pull test negative
- Trichoscopy: anisotrichosis
- Diagnosis: Androgenetic Alopecia, Hamilton-Norwood III vertex
- Previous treatment: topical minoxidil. He suffered from contact dermatitis after using it.
- Proposed treatment: finasteride 1 mg q.o + dermocosmetic leave-on topical serum containing 1.5% Aminexil and Octopirox daily during 3 months and later three times a week.
- Androgenetic alopecia is the most common type of hair loss and it is associated with a high psychological burden, reduced quality of life, poor body image and low self-esteem, particularly in young men.
- The severity of quality of life involvement does not always correlate with the severity of alopecia.
- Androgenetic alopecia treatment is chronic and requires high patient’s compliance to be effective.
- Treatment results usually takes months to start to become apparent and this may be disappointing for patients.
- Combination therapies achieved better and faster results than monotherapy.
- Standard of care of male androgenetic alopecia usually combines 5 alfa reductase inhibitor and topical minoxidil. The most common side effect of topical minoxidil is irritant contact dermatitis which limits its use.
- Dermocosmetic leave-on topical serum containing 1.5% Aminexil and Octopirox has shown a strong anti‐lysyl hydroxylase activity in vitro as well as its benefit in subjects with mild AGA.
- A recent published cosmetic, open‐label, observational, international real‐life study reported that the shampoo improves hair loss and hair quality in subjects with mild AGA with an excellent tolerability, a pleasant texture, and a high satisfaction rate.
- This clinical case’s results match the published data as the patient was greatly satisfied with the results in terms of hair growth and scalp coverage and the tolerance and cosmetic properties of the shampoo.
- The shampoo is a good topical adjuvant therapy for male androgenetic alopecia.
Clinical and Trichoscopic evaluation
Clinical pictures
Trichoscopic pictures
Bibliography
- EXPERT OPINION ON DRUG SAFETY, 2018 https://doi.org/10.1080/14740338.2018.1430765 Androgenetic alopecia; drug safety and therapeutic strategies Ion G. Motofei, David L. Rowland, Daniela L. Baconi, et al.
- J Cosmet Dermatol 2023 Jan;22(1):89-95. doi: 10.1111/jocd.14983. Epub 2022 Apr 25. The psychological consequences of androgenetic alopecia: A systematic review Erica L Aukerman 1, Mohammad Jafferany 2
- Dermatol Ther 2022 Mar;35(3):e15262. doi: 10.1111/dth.15262.Efficacy comparison of monotherapies and combination therapies for androgenetic alopecia: A Bayesian network meta-análisis.
- Dermatol Ther. 2021 Nov-Dec; 34(6): e15134. An anti‐hair loss treatment in the management of mild androgenetic alopecia: Results from a large, international observational study. Pascal Reygagne, Victor Desmond Mandel, Catherine Delva, e al.